Latest Updates

    None Found

Featured Speakers

  • Sarah Scharfenaker, MA, CCC-SLP, fondly known as “Mouse”, is co-founder of Developmental FX. She has worked in the fields of fragile X syndrome and neurodevelopmental disorders for more than 20 years. She provided speech pathology services to the Denver Fragile X Treatment and Research Center at The Children’s Hospital in Denver, Colorado, and accompanied Dr. Randi Hagerman to the UC Davis M.I.N.D. Institute to initiate its program. Mouse has published many chapters and articles on intervention for Fragile X. She consults and lectures on Fragile X treatment both nationally and internationally.
  • Tracy Murnan Stackhouse, MA, OTR is co-founder of the Developmental FX in Denver, Colorado. She is a leading pediatric occupational therapist involved in clinical treatment, research, mentoring, and training regarding OT intervention and neurodevelopmental disorders, especially fragile X syndrome and autism. Tracy has a master’s degree in developmental psychology. She is NDT trained, SIPT Certified. Tracy has written several book chapters on sensory integration and neurodevelopmental disorders, and teaches nationally and internationally on sensory integration, fragile X and related topics.
  • Sharyn Lincoln, M.S., C.G.C. is a Licensed Genetic Counselor and the Program Coordinator of the Fragile X Program at Children’s Hospital Boston in Boston, Massachusetts. Ms. Lincoln provides genetic counseling to individuals and families with fragile X syndrome and fragile X-related disorders. As Program Coordinator for the CHB Fragile X Program, she coordinates visits to the Program and participates and contributes to diagnostic evaluations within the Program.
  • Craig Penz is a Clinical Program Manager for Seaside Therapeutics. He received his Bachelor’s of Science in biology at Cornell University with a specialization in neurobiology and is currently pursuing a Master’s in Clinical Investigation at Boston University. Has over eight years experience managing clinical trials and has worked on Seaside Therapeutics’ Fragile X Syndrome and Autism Spectrum Disorder studies for over three years.